Cormedix earnings were $181.0M for the trailing 12 months ending Mar 31, 2026, with 792.3% growth year over year. The latest CRMD earnings report on Mar 31, 2026 announced Q1 2026 earnings of $38.6M, up 175.3% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, CRMD reported annual earnings of $163.1M, with -1,009.4% growth.
CRMD past earnings growth
How has CRMD's earnings growth performed historically?
Cormedix (NASDAQ: CRMD) reported Q1 2026 earnings per share (EPS) of $0.48, up 50% year over year. Total CRMD earnings for the quarter were $38.60 million. In the same quarter last year, Cormedix's earnings per share (EPS) was $0.32.
As of the last Cormedix earnings report, Cormedix is currently profitable. Cormedix's net profit (also called net income) for the twelve months ending Mar 31, 2026 was $181.01 million, a 953.61% increase year over year.
What was CRMD's earnings growth in the past year?
As of Cormedix's earnings date in Q2 2026, Cormedix's earnings has grown 792.31% year over year. This is 744.97 percentage points higher than the US Biotechnology industry earnings growth rate of 47.34%. CRMD earnings in the past year totalled $181.01 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.